Please assess the completion status of the following clinical trial:

Trial Title: Study of Posoleucel (ALVR105,Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Any age at the day of screening visit.~* No known or suspected clinically significant disease from AdV, BKV, CMV, EBV, HHV-6, and/or JCV~* Within 25 days of receiving a first allogeneic HCT and have demonstrated clinical engraftment at time of dosing~* Meet one or more of the following criteria at the time of randomization:~  * Related (sibling) donor with at least one mismatch at one of these HLA-gene loci: HLA-A, -B or -DR~ * Haploidentical donor~ * Matched or Mismatched unrelated donor~ * Use of umbilical cord blood as stem cell source~ * Ex vivo graft manipulation resulting in T cell depletion~ * Received anti-thymocyte globulin or alemtuzumab (Campath-1H)~Key Exclusion Criteria:~* History of AdV, BKV, CMV, EBV, HHV-6, and/or JCV end-organ disease within 6 months prior to randomization~* Evidence of active Grade \>2 acute GVHD~* Presence of non-minor uncontrolled or progressive bacterial, viral or fungal infections~* Known history or current (suspected) diagnosis of Grade ≥3 CRS requiring treatment associated with the administration of peptides, proteins, and/or antibodies~* Ongoing therapy with high-dose systemic corticosteroids (ie, prednisone equivalent dose \>1.0 mg/kg/day) within 24 hours prior to dosing~* Relapse of primary malignancy other than minimal residual disease~Note: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Posoleucel (ALVR105) (Type: EXPERIMENTAL): Administered as 2-4 milliliter infusion, visually identical to placebo
- Placebo (Type: PLACEBO_COMPARATOR): Administered as 2-4 milliliter infusion, visually identical to Posoleucel (ALVR105)

Based on this trial design, predict the completion outcome and termination type (if applicable).